U.S. patent application number 12/479450 was filed with the patent office on 2010-03-18 for lipid-amino acid conjugates and methods of use.
This patent application is currently assigned to University of Massachusetts. Invention is credited to Sumner H. Burstein, Robert B. Zurier.
Application Number | 20100069491 12/479450 |
Document ID | / |
Family ID | 35785810 |
Filed Date | 2010-03-18 |
United States Patent
Application |
20100069491 |
Kind Code |
A1 |
Burstein; Sumner H. ; et
al. |
March 18, 2010 |
LIPID-AMINO ACID CONJUGATES AND METHODS OF USE
Abstract
N-fatty acid-amino acid conjugates and J.sub.2 prostanoid-amino
acid conjugates are disclosed along with methods for making such
conjugates and methods of using these conjugates in the treatment
of conditions that involve dysfunctional lipid metabolism, insulin
sensitivity, glucose homeostasis, and/or inflammation.
Inventors: |
Burstein; Sumner H.;
(Framingham, MA) ; Zurier; Robert B.; (Princeton,
MA) |
Correspondence
Address: |
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS
MN
55440-1022
US
|
Assignee: |
University of Massachusetts
Boston
MA
|
Family ID: |
35785810 |
Appl. No.: |
12/479450 |
Filed: |
June 5, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11183055 |
Jul 15, 2005 |
7544714 |
|
|
12479450 |
|
|
|
|
60588697 |
Jul 16, 2004 |
|
|
|
Current U.S.
Class: |
514/559 ;
554/110 |
Current CPC
Class: |
A61K 31/401 20130101;
A61P 37/06 20180101; A61P 3/10 20180101; A61P 29/00 20180101; C07C
233/47 20130101; A61P 19/02 20180101; C07C 233/49 20130101; A61K
31/202 20130101; A61P 17/06 20180101; A61P 31/18 20180101 |
Class at
Publication: |
514/559 ;
554/110 |
International
Class: |
A61K 31/20 20060101
A61K031/20; C07C 229/02 20060101 C07C229/02; A61P 29/00 20060101
A61P029/00; A61P 3/10 20060101 A61P003/10; A61P 31/18 20060101
A61P031/18; A61P 17/06 20060101 A61P017/06; A61P 37/06 20060101
A61P037/06 |
Goverment Interests
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with support from NIH grant numbers
DA12178 and DA017969; therefore, the government has certain rights
in the invention.
Claims
1. A compound having the following general formula (Formula I)
##STR00009## wherein R.sub.1 is a hydrocarbon chain of a fatty acid
selected from the group consisting of myristic acid, palmitic acid,
stearic acid, oleic acid, linoleic acid, eicosatrienoic acid,
arachidonic acid, eicosapentenoic acid, and docosatetraenoic acid;
and wherein (a) R.sub.4 is a hydrogen, and R.sub.2 and R.sub.3
together form a cyclic side chain of an amino acid analog selected
from the group consisting of 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, and 1-amino-cyclohexane
carboxylic acid; (b) R.sub.4 is a hydrogen, and R.sub.2 and R.sub.3
are two methyl groups of 2-aminoisobutyric acid; (c) R.sub.3 and
R.sub.4 are hydrogens, and R.sub.2 is a side chain of a
phenyl-glycine or a phenyl-glycine derivative; (d) R.sub.3 and
R.sub.4 are hydrogens, and R.sub.2 is a side chain of a
phenyl-alanine derivative; (e) R.sub.3 is a hydrogen, and R.sub.2
and R.sub.4, together, form a side chain of a proline derivative;
(f) R.sub.3 and R.sub.4 are hydrogens, and R.sub.2 is a side chain
of an amino acid selected from the group consisting of serine,
threonine, methionine, phenylalanine, tyrosine, lysine, aspartic
acid, and glutamic acid, and the C.alpha. has the same
stereochemistry as a D amino acid; or (g) R.sub.3 is a hydrogen,
and R.sub.2 and R.sub.4, together, form D-proline.
2. The compound of claim 1, wherein the fatty acid is arachidonic
acid.
3. A compound having the following general formula (Formula I):
##STR00010## wherein R.sub.1 is a hydrocarbon chain of a
non-mammalian fatty acid or J.sub.2 prostanoid selected from the
group consisting of pentadecanoic acid; heptadecanoic acid;
nonadecanoic acid; heneicosanoic acid; 9-trans-tetradecanoic acid,
14:1T; 10-trans-pentadecanoic acid, 15:1T; 9-trans-hexadecenoic
acid, 16:1T; 10-heptadecenoic acid, 17:1; 10-trans-heptadecenoic
acid, 17:1T; 7-trans-nonadecenoic acid, 19:1T;
10,13-nonadecadienoic acid, 19:2; 11-trans-eicosenoic acid, 20:1T;
12-heneicosenoic acid, 21:1; prostaglandin J.sub.2;
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2;
.DELTA..sup.12-prostaglandin J.sub.2; and
9,10-dihydro-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2; and
wherein (a) R.sub.4 is a hydrogen, and R.sub.2 and R.sub.3 together
form a cyclic side chain of an amino acid analog selected from the
group consisting of 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, and 1-amino-cyclohexane
carboxylic acid; (b) R.sub.4 is a hydrogen, and R.sub.2 and R.sub.3
are two methyl groups of 2-aminoisobutyric acid (c) R.sub.3 and
R.sub.4 are hydrogens, and R.sub.2 is a side chain of a
phenyl-glycine or a phenyl-glycine derivative; (d) R.sub.3 and
R.sub.4 are hydrogens, and R.sub.2 is a side chain of a
phenyl-alanine derivative; (e) R.sub.3 is a hydrogen, and R.sub.2
and R.sub.4 together form a side chain of a proline or a proline
derivative; or (f) R.sub.3 and R.sub.4 are hydrogens, and R.sub.2
is a side chain of an amino acid selected from the group consisting
of glycine, alanine, valine, leucine, isoleucine, serine,
threonine, methionine, phenylalanine, tyrosine, lysine, aspartic
acid, glutamic acid, asparagine, and glutamine.
4. (canceled)
5. A pharmaceutical composition comprising the compound of claim
1.
6. A pharmaceutical composition comprising the compound of claim
2.
7. A pharmaceutical composition comprising the compound of claim
3.
8. (canceled)
9. A method of treating inflammation of bodily tissue of a subject,
the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
5.
10. A method of treating inflammation of bodily tissue of a
subject, the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
6.
11. A method of treating inflammation of bodily tissue of a
subject, the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
7.
12. (canceled)
13. A method of treating a subject in need of treatment for type II
diabetes, the method comprising administering to the subject a
therapeutic amount of a pharmaceutical composition comprising an
N-fatty acid-amino acid conjugate or J.sub.2 prostanoid-amino acid
conjugate.
14. The method of claim 13, wherein the pharmaceutical composition
comprises a compound having the following general formula (Formula
I) ##STR00011## wherein: (a) R.sub.1 is a non-carboxyl portion of a
fatty acid or J.sub.2 prostanoid selected from the group consisting
of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic
acid, eicosatrienoic acid, arachidonic acid, eicosapentenoic acid,
docosatetraenoic acid, prostaglandin J.sub.2,
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2,
.DELTA..sup.12-prostaglandin J.sub.2, and
9,10-dihydro-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2; and
R.sub.3 and R.sub.4 are hydrogens, and R.sub.2 is a side chain of
an amino acid selected from the group consisting of glycine,
alanine, valine, leucine, isoleucine, asparagine, and glutamine; or
(b) R.sub.1 is a hydrocarbon chain of arachidonic acid; and R.sub.3
and R.sub.4 are hydrogens, and R.sub.2 is the side chain of an
amino acid selected from the group consisting of glycine, alanine,
valine, leucine, isoleucine, asparagine, and glutamine.
15. A method of treating a subject in need of treatment for type II
diabetes, the method comprising administering to the subject a
therapeutic amount of the pharmaceutical composition of claim
5.
16. A method of treating a subject in need of treatment for type II
diabetes, the method comprising administering to the subject a
therapeutic amount of the pharmaceutical composition of claim
6.
17. A method of treating a subject in need of treatment for type II
diabetes, the method comprising administering to the subject a
therapeutic amount of the pharmaceutical composition of claim
7.
18. (canceled)
19. A method of treating a subject in need of treatment for HIV
virus infection, the method comprising: (i) administering to the
subject an effective amount of treatment with an HIV protease
inhibitor cocktail; and (ii) co-administering to the subject a
therapeutic amount of the pharmaceutical composition of claim
5.
20. (canceled)
21. A method of treating psoriasis or rheumatoid arthritis in a
subject, the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
5.
22. A method of treating psoriasis or rheumatoid arthritis in a
subject, the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
6.
23. A method of treating psoriasis or rheumatoid arthritis in a
subject, the method comprising administering to the subject an
anti-inflammatory amount of the pharmaceutical composition of claim
7.
24. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of the filing date of
U.S. Provisional Patent Application Ser. No. 60/588,697, filed on
Jul. 16, 2004. The contents of this prior application are hereby
incorporated by reference in their entirety.
TECHNICAL FIELD
[0003] This invention relates to lipid-amino acid conjugates and
methods of making and using the conjugates in the treatment of
conditions that involve, for example, dysfunctional lipid
metabolism, insulin sensitivity, glucose homeostasis, and/or
inflammation. The invention relates to the fields of molecular
biology, medicinal chemistry, pharmacology, and medicine.
BACKGROUND
[0004] Lipoamino acids are a class of molecules first identified in
bacteria that consist of a fatty acid moiety conjugated to an amino
acid (Kawazoe et al., J. Bacterial., 173:5470-5475, 1991). At least
three fatty acid-amino acid conjugates are natural constituents of
the mammalian brain: N-arachidonylglycine (NAGly),
N-arachidonyl-4-aminobutyric acid (NAGABA), and
N-arachidonylalanine (NAAla). NAGly is an endogenous constituent of
many tissues, including spinal cord, small intestines, kidneys,
glabourous skin, heart, lung, liver, spleen, testes, and blood
(Huang et al., J. Biol. Chem., 276:46, 2001). NAGly is a structural
analog of the endogenous cannabinoid anandamide, although it has
been reported to lack affinity for the cannabinoid receptors CB1
and CB2, the vanilloid VR1 receptor, and the anandamide transporter
(Huang et al., 2001, supra; Burstein et al., Prostaglandins and
Other Lipid Mediat., 61:29-41, 2000). NAGly has been reported to
have analgesic properties.
SUMMARY
[0005] The present invention relates to lipid-amino acid
conjugates, for example, N-fatty acid-amino acid conjugates, which
can be referred to as "elmiric acids," and J.sub.2 prostanoid-amino
acid conjugates, which can be referred to as "3 acids," methods of
synthesizing such conjugates, and methods of treating various
disorders, including, e.g., inflammation, pain, conditions related
to dysfunctional lipid metabolism, HIV, and type II diabetes, with
such conjugates.
[0006] Certain conjugates disclosed herein have the following
general formula (Formula I):
##STR00001##
[0007] In Formula I, R.sub.1, R.sub.2, R.sub.3, and R.sub.4
represent chemical groups. The conjugates disclosed have at least
one of the following features: (a) R.sub.1 is a substituent of a
non-mammalian fatty acid or (b) R.sub.2 and R.sub.3 are
substituents of an amino acid analog. R.sub.1 can be the
non-carboxyl portion (tail) of a J.sub.2 prostanoid, e.g., a
mammalian or a non-mammalian J.sub.2 prostanoid, or a fatty acid,
e.g., a mammalian fatty acid or a non-mammalian fatty acid. Certain
compounds disclosed herein have the structure of Formula I, in
which R.sub.1 is the hydrocarbon chain of a mammalian fatty acid,
and R.sub.2, R.sub.3, and R.sub.4 are substituents of an amino acid
analog. Other compounds disclosed herein have the structure of
Formula I, in which R.sub.1 is a tail (non-carboxyl portion) of a
non-mammalian fatty acid or J.sub.2 prostanoid, and R.sub.2,
R.sub.3, and R.sub.4 are substituents of (i) a natural amino acid
or (ii) an amino acid analog.
[0008] Other conjugates disclosed herein include a dipeptide
conjugated to a fatty acid or J.sub.2 prostanoid. These conjugates
have the following general formula (Formula II):
##STR00002##
In Formula II, R.sub.1 can be the hydrocarbon chain of either a
J.sub.2 prostanoid or a mammalian or non-mammalian fatty acid. The
pairs of substituents R.sub.2 and R.sub.3, and R.sub.4 and R.sub.5,
each form an amino acid residue in combination with the respective
alpha carbon. In Formula II, each amino acid can be, independently,
a natural amino acid or an amino acid analog.
[0009] Thus, in one aspect, a conjugate disclosed herein has the
structure of Formula I, and R.sub.1 is the hydrocarbon chain of a
mammalian fatty acid, e.g., myristic acid, palmitic acid, stearic
acid, oleic acid, linoleic acid, linolenic acid, eicosatrienoic
acid, arachidonic acid, eicosapentenoic acid, and docosatetraenoic
acid. In some embodiments of this aspect, R.sub.4 is a hydrogen,
and R.sub.2 and R.sub.3 together form a cyclic side chain of an
amino acid analog, such as 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, and 1-amino-cyclohexane
carboxylic acid. In other embodiments, R.sub.4 is, e.g., a
hydrogen, and R.sub.2 and R.sub.3 are the two methyl groups of
2-aminoisobutyric acid. In still other embodiments, R.sub.3 and
R.sub.4 are, e.g., hydrogens, and R.sub.2 is the side chain of a
phenyl-glycine or a phenyl-glycine derivative. In yet other
embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2
is the side chain of a phenyl-alanine derivative. In other
embodiments, R.sub.3 is, e.g., a hydrogen, and R.sub.2 and R.sub.4
together form the side chain of a proline derivative. In different
embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2
is the side chain of an amino acid selected from the group
consisting of: serine, threonine, methionine, phenylalanine,
tyrosine, lysine, aspartic acid, and glutamic acid, and the
C.alpha. has the same stereochemistry as a D amino acid. In further
embodiments, R.sub.3 is, e.g., a hydrogen, and R.sub.2 and R.sub.4,
together, form D-proline. In certain embodiments, R.sub.4 can be a
hydrogen, methyl or ethyl group.
[0010] In another aspect, a conjugate disclosed herein has the
structure of Formula I, and R.sub.1 is the hydrocarbon chain of
arachidonic acid. In some embodiments of this aspect, R.sub.4 is,
e.g., a hydrogen, and R.sub.2 and R.sub.3 together form the cyclic
side chain of an amino acid analog, such as, 1-amino-cyclopropane
carboxylic acid, 1-amino-cyclopentane carboxylic acid, and
1-amino-cyclohexane carboxylic acid. In other embodiments, R.sub.4
is, e.g., a hydrogen, and R.sub.2 and R.sub.3 are the two methyl
groups of 2-aminoisobutyric acid. In still other embodiments,
R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2 is the side
chain of a phenyl-glycine or a phenyl-glycine derivative. In yet
other embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and
R.sub.2 is the side chain of a phenyl-alanine derivative. In other
embodiments, R.sub.3 is, e.g., a hydrogen, and R.sub.2 and R.sub.4
together form the side chain of a proline derivative. In different
embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2
is the side chain of an amino acid selected from the group
consisting of: serine, threonine, methionine, phenylalanine,
tyrosine, lysine, aspartic acid, and glutamic acid, and the
C.alpha. has the same stereochemistry as a D amino acid. In further
embodiments, R.sub.3 is, e.g., a hydrogen, and R.sub.2 and R.sub.4,
together, form D-proline. In certain embodiments, R.sub.4 can be a
hydrogen, methyl or ethyl group.
[0011] In a different aspect, a conjugate disclosed herein has the
structure of Formula I, and R.sub.1 is the hydrocarbon chain of a
non-mammalian fatty acid, e.g., pentadecanoic acid; heptadecanoic
acid; nonadecanoic acid; heneicosanoic acid; 9-trans-tetradecanoic
acid, 14:1T; 10-trans-pentadecanoic acid, 15:1T;
9-trans-hexadecenoic acid, 16:1T; 10-heptadecenoic acid, 17:1;
10-trans-heptadecenoic acid, 17:1T; 7-trans-nonadecenoic acid,
19:1T; 10,13-nonadecadienoic acid, 19:2; 11-trans-eicosenoic acid,
20:1T; and 12-heneicosenoic acid, 21:1. In some embodiments of this
aspect, R.sub.4 is, e.g., a hydrogen, and R.sub.2 and R.sub.3
together form the cyclic side chain of an amino acid analog, e.g.,
1-amino-cyclopropane carboxylic acid, 1-amino-cyclopentane
carboxylic acid, and 1-amino-cyclohexane carboxylic acid. In other
embodiments, R.sub.4 is, e.g., a hydrogen, and R.sub.2 and R.sub.3
are the two methyl groups of 2-aminoisobutyric acid. In still other
embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2
is the side chain of a phenyl-glycine or a phenyl-glycine
derivative. In yet other embodiments, R.sub.3 and R.sub.4 are,
e.g., hydrogens, and R.sub.2 is the side chain of a phenyl-alanine
derivative. In other embodiments, R.sub.3 is, e.g., a hydrogen, and
R.sub.2 and R.sub.4 together form the side chain of a proline or a
proline derivative.
[0012] In certain other embodiments, R.sub.3 and R.sub.4 are, e.g.,
hydrogens, and R.sub.2 is the side chain of a D- or L-enantiomer of
an amino acid, e.g., glycine, alanine, valine, leucine, isoleucine,
serine, threonine, methionine, phenylalanine, tyrosine, lysine,
aspartic acid, glutamic acid, asparagine, and glutamine. In certain
embodiments, R.sub.4 can be a hydrogen, methyl or ethyl group.
[0013] In another aspect, a conjugate disclosed herein has the
structure of Formula I, and R.sub.1 is the non-carboxyl portion of
a J.sub.2 prostanoid, e.g., prostaglandin J.sub.2,
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2,
.DELTA..sup.12-prostaglandin J.sub.2, or
9,10-dihydro-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2. In
some embodiments of this aspect, R.sub.4 is, e.g., a hydrogen, and
R.sub.2 and R.sub.3 together form the cyclic side chain of an amino
acid analog, e.g., 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, and 1-amino-cyclohexane
carboxylic acid. In other embodiments, R.sub.4 is, e.g., a
hydrogen, and R.sub.2 and R.sub.3 are the two methyl groups of
2-aminoisobutyric acid. In still other embodiments, R.sub.3 and
R.sub.4 are, e.g., hydrogens, and R.sub.2 is the side chain of a
phenyl-glycine or a phenyl-glycine derivative. In yet other
embodiments, R.sub.3 and R.sub.4 are, e.g., hydrogens, and R.sub.2
is the side chain of a phenyl-alanine derivative. In other
embodiments, R.sub.3 is, e.g., a hydrogen, and R.sub.2 and R.sub.4
together form the side chain of a proline or a proline derivative.
In certain other embodiments, R.sub.3 and R.sub.4 are, e.g.,
hydrogens, and R.sub.2 is the side chain of a D- or L-enantiomer of
an amino acid, e.g., glycine, alanine, valine, leucine, isoleucine,
serine, threonine, methionine, phenylalanine, tyrosine, lysine,
aspartic acid, glutamic acid, asparagine, and glutamine. In certain
embodiments, R.sub.4 can be a hydrogen, methyl or ethyl group.
[0014] In yet another aspect, a conjugate disclosed herein has the
structure of Formula II, and R.sub.1 can be the hydrocarbon chain
of a J.sub.2 prostanoid or a fatty acid, e.g., a mammalian fatty
acid or a non-mammalian fatty acid. In this aspect, R.sub.2 and
R.sub.3 are substituents of a natural amino acid or an amino acid
analog; and R.sub.4 and R.sub.5 are substituents of a natural amino
acid or an amino acid analog, such that the compound consists of a
fatty acid amide linked to a dipeptide.
[0015] In another aspect, the invention provides pharmaceutical
compositions that include one or more of the conjugates disclosed
herein. These pharmaceutical compositions can be used in the
methods of treatment that constitute yet another aspect of the
invention. In these methods of treatment, a pharmaceutical
composition that includes a therapeutically effective amount of one
or more conjugates described herein is administered to a subject
suffering from a medical condition, such as inflammation, e.g.,
psoriasis or rheumatoid arthritis, type 2 diabetes, and/or the side
effects associated with antiviral protease inhibitors, such as
anti-HIV protease cocktails, to treat such condition.
[0016] A "lipid-amino acid conjugate" is an N-conjugate of a lipid
acid, e.g., a J.sub.2 prostanoid or fatty acid, and an amino
acid.
[0017] "Elmiric acid," as used herein, refers to an N-fatty
acid-amino acid conjugate with a structure described by Formula I
or Formula II, as defined herein.
[0018] "J acid," as used herein, refers to a J.sub.2
prostanoid-amino acid conjugate with a structure described by
Formula I or Formula II, as defined herein.
[0019] "N-fatty acid-amino acid conjugate" is used herein
interchangeably with "N-fatty acid-amino conjugate."
[0020] A mammalian fatty acid is a natural or synthetic fatty acid
that is identical in structure to one naturally produced in a
mammal, including, but not limited to, myristic acid, palmitic
acid, stearic acid, oleic acid, linoleic acid, linolenic acid,
eicosatrienoic acid, arachidonic acid, eicosapentenoic acid, and
docosatetraenoic acid.
[0021] A non-mammalian fatty acid is a natural or synthetic fatty
acid not normally produced by a mammal, including, but not limited
to, pentadecanoic acid; heptadecanoic acid; nonadecanoic acid;
heneicosanoic acid; 9-trans-tetradecanoic acid, 14:1T;
10-trans-pentadecanoic acid, 15:1T; 9-trans-hexadecenoic acid,
16:1T; 10-heptadecenoic acid, 17:1; 10-trans-heptadecenoic acid,
17:1T; 7-trans-nonadecenoic acid, 19:1T; 10,13-nonadecadienoic
acid, 19:2; 11-trans-eicosenoic acid, 20:1T; and 12-heneicosenoic
acid, 21:1.
[0022] J.sub.2 prostanoid, as used herein, refers to prostaglandin
J2 and its derivatives and analogs, including but not limited to
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2,
.DELTA..sup.12-prostaglandin J.sub.2, and
9,10-dihydro-15-deoxy-.DELTA..sup.12'.sup.14-prostaglandin
J.sub.2.
[0023] The term "natural amino acid," as used herein, refers to
L-amino acids found in nature and excludes D-amino acids and amino
acid analogs.
[0024] The term "amino acid analog," as used herein, includes
non-naturally occurring L-amino acids and D-amino acids, whether
naturally or non-naturally occurring, as well as N-substituted
amino acids, e.g., N-methyl and N-ethyl amino acids.
[0025] Dipeptides, as used herein, refers to two amide linked
chemical groups, wherein each chemical group is independently a
natural amino acid or an amino acid analog.
[0026] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, suitable methods and materials are described below. All
publications, patent applications, patents, and other references
mentioned herein are incorporated by reference in their entirety.
In case of conflict, the present specification, including
definitions, will control. In addition, the materials, methods, and
examples are illustrative only and not intended to be limiting.
[0027] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
BRIEF DESCRIPTION OF DRAWINGS
[0028] FIG. 1 is a list of exemplary fatty acids that can be used
to make an elmiric acid.
[0029] FIG. 2 is a list of exemplary amino acids that can be used
to make an elmiric acid or J acid.
[0030] FIG. 3 is a list of exemplary cyclic amino acid analogs that
can be used to make an elmiric acid or J acid. The arrow denotes
the alpha carbon of the amino acid analog, and R denotes the amino
group, which can be used to form an amide linkage to a fatty acid
molecule or J.sub.2 prostanoid, thereby forming an N-fatty
acid-amino acid conjugate or J.sub.2 prostanoid-amino acid
conjugate.
[0031] FIG. 4 is a list of exemplary amino acid analogs, including
phenyl-glycine and phenyl-glycine derivatives, that can be used to
make an elmiric acid or J acid.
[0032] FIG. 5 is a list of exemplary phenyl-alanine derivatives
that can be used to make an elmiric acid or J acid.
[0033] FIG. 6 is a list of exemplary dipeptides that can be used to
make an elmiric acid or J acid.
[0034] FIG. 7 is a representation of an exemplary synthesis scheme
that can be used to make an elmiric acid or J acid.
[0035] FIG. 8 is a representation of an exemplary synthesis scheme
that can be used to make an elmiric acid or J acid.
[0036] FIG. 9 is a list of exemplary J.sub.2 prostanoids that can
be used to make a J acid.
DETAILED DESCRIPTION
[0037] Lipid-amino acid conjugates, e.g., elmiric acids (N-fatty
acid-amino acid conjugates) and J acids (J.sub.2 prostanoid-amino
acid conjugates), and methods of making and using them are
disclosed herein. These conjugates contain at least one of the
following chemical groups: a non-mammalian fatty acid, a J.sub.2
prostanoid, an amino acid analog, or a dipeptide. To facilitate
appreciation of the invention, the conjugates can be classified in
three groups. In a first group, the conjugates contain the
hydrocarbon chain (tail) of a mammalian fatty acid, the carboxyl
group of which has reacted with the amino residue of an amino acid
analog to form an amide linked N-fatty acid-amino acid conjugate.
In a second group, the conjugates contain the non-carboxyl portion
(tail) of a non-mammalian fatty acid or a J.sub.2 prostanoid, the
carboxyl group of either of which has reacted with the amino
residue of either an amino acid analog or a natural amino acid to
form an amide linked N-fatty acid-amino acid conjugate or an amide
linked J.sub.2 prostanoid-amino acid conjugate. In a third group,
the conjugates contain a dipeptide, the amino terminus of which has
reacted with the carboxyl group of either a J.sub.2 prostanoid, a
mammalian fatty acid, or a non-mammalian fatty acid to form an
amide linked N-fatty acid-amino acid conjugate or an amide linked
J.sub.2 prostanoid-amino acid conjugate. The phrase "has reacted
with," as used above, simply provides help in the visualization of
the structure, and is not an implicit limitation on how the
compounds can be made. These elmiric acids and J acids can be used
to treat various disorders, including those associated with
dysfunctional lipid metabolism, insulin sensitivity, glucose
homeostasis, and/or inflammation.
Lipid-Amino Acid Conjugates
[0038] Certain lipid-amino acid conjugates disclosed can be
represented by the following general formula (Formula I):
##STR00003##
In Formula I, C.sub..alpha. is the alpha-carbon of a natural amino
acid or an amino acid analog. The R.sub.1, R.sub.2, R.sub.3, and
R.sub.4 groups are as defined elsewhere herein.
1. Elmiric Acids Including a Mammalian Fatty Acid
[0039] In one aspect, an elmiric acid has the structure of Formula
I, and R.sub.1 is the hydrocarbon chain (or tail) of a mammalian
fatty acid, e.g., myristic acid, 14:0; palmitic acid, 16:0; stearic
acid, 18:0; oleic acid, 18:1; linoleic acid, 18:2; linolenic acid,
18:3; eicosatrienoic acid, 20:3; arachidonic acid, 20:4;
eicosapentenoic acid, 20:5; or docosatetraenoic acid, 22:4.
Exemplary mammalian fatty acids are listed in FIG. 1. All of the
compounds listed in FIG. 1 are available from Nu-Check Prep, Inc.
(Elysian, Minn.).
[0040] In certain embodiments of this aspect, R.sub.4 is, e.g., a
hydrogen, and R.sub.2 and R.sub.3 together form the cyclic side
chain of an amino acid analog that can be, e.g.,
1-amino-cyclopropane carboxylic acid, 1-amino-cyclopentane
carboxylic acid, or 1-amino-cyclohexane carboxylic acid. In other
embodiments, R.sub.4 is, e.g., a hydrogen, and R.sub.2 and R.sub.3
represent the two methyl side chains of 2-aminoisobutyric acid. In
both of these embodiments where R.sub.2 and R.sub.3 are
substituents of an amino acid analog depicted in FIG. 3, the
alpha-carbon of Formula I is the carbon marked by an arrow in FIG.
3. The "R" in FIG. 3 denotes the amino group that can be used to
form an amide linkage to a fatty acid molecule, thereby forming an
N-fatty acid-amino acid conjugate. All of the amino acid analogs
listed in FIG. 3 are available from Sigma-Aldrich (St. Louis,
Mo.).
[0041] In other embodiments, R.sub.2 is the phenyl side chain of a
phenylglycine or a phenyl-glycine derivative, such that R.sub.2 has
the following general structure (Formula III):
##STR00004##
In these embodiments, R.sub.3 and R.sub.4 are, e.g., H, and R.sub.2
has the structure of Formula III, wherein X can be, e.g., H, OH,
CH.sub.2NH.sub.2, and SO.sub.3. Exemplary phenyl-glycine
derivatives are listed in FIG. 4, all of which are available from
RSP Amino Acid Analogues, Inc. (Hopkinton, Mass.).
[0042] In yet other embodiments, R.sub.2 is a methylene-phenyl side
chain of a phenylalanine derivative, such that R.sub.2 has the
following general structure (Formula IV):
##STR00005##
In these embodiments, R.sub.3 and R.sub.4 are, e.g., H, and R.sub.2
has the structure of Formula IV, wherein the set of substituents
corresponding to X, Y, and Z, can independently be, e.g., H, OH,
OCH.sub.3, F, Cl, I, CH.sub.3, C.sub.2H.sub.5, i-C.sub.3H.sub.7,
NH--CO--CH.sub.3, SH, NH.sub.2, CN, CH.sub.2NH.sub.2, COOH, CHO,
NO.sub.2, CONH.sub.2, COCH.sub.3, or CH.sub.2OH. In specific
examples, X, Y, and Z (X, Y, Z), respectively, can be: (H, OH, H);
(H, OCH.sub.3, H); (H, H, OH); (H, H, OCH.sub.3); (I, H, H);
(CH.sub.3, H, H); (NH--CO--CH.sub.3, H, H); (SH, H, H); (NH.sub.2,
H, H); (Cl, H, H); (CN, H, H); (CH.sub.2NH.sub.2, H, H); (COOH, H,
H); (NO.sub.2, H, H); (CHO, H, H); (C.sub.2H.sub.5, H, H);
(i-C.sub.3H.sub.7, H, H); (OCH.sub.3, H, H); (CONH.sub.2, H, H);
(COCH.sub.3, H, H); (H, NO.sub.2, H); (F, H, H); (H, NH.sub.2, H),
and (CH.sub.2OH, H, H). Note that in the immediately preceding
group of substituent sets, each set of substituents marked off by
parenthesis is arranged in the following manner (X substituent, Y
substituent, and Z substituent), consistent with the phenylalanine
derivatives shown in FIG. 5. All of the compounds listed in FIG. 5
are available from RSP Amino Acid Analogues, Inc.
[0043] In still other embodiments, R.sub.3 is, e.g., H and R.sub.2
and R.sub.4 together form a proline derivative, such that R.sub.2
and R.sub.4 together form one of the following structures (Formulas
V, VI, and VII):
##STR00006##
In these embodiments, R.sub.2 and R.sub.4 together form the
structure of any one of Formulas V, VI, and VII and the arrow
denotes the .alpha.-carbon of Formula I. The R.sub.1 hydrocarbon
chain of a fatty acid is amide linked to the nitrogen molecule in
the ring structure of Formulas V, VI, and VII, thereby forming an
N-fatty acid-amino acid conjugate. In embodiments where R.sub.2 and
R.sub.4 form the ring structure of Formula V, X can be, e.g., CN,
CHO, CH.sub.2OH, CH.sub.2NH.sub.2, COOH, CH.sub.2CN, NH.sub.2, or
phenyl.
[0044] In further embodiments, R.sub.3 and R.sub.4 are, e.g.,
hydrogens, and R.sub.2 forms a D-amino acid (other than glycine)
listed in FIG. 2. R.sub.2 can be the side chain of a D-amino acid
such as alanine, valine, leucine, isoleucine, serine, threonine,
methionine, phenylalanine, tyrosine, lysine, aspartic acid,
glutamic acid, asparagine, or glutamine. In other embodiments of
this aspect, R.sub.2 and R.sub.3 are, e.g., H, thereby forming a
glycine conjugate. In other embodiments, R.sub.3 is H, and R.sub.2
and R.sub.4 together form D-proline. The amino acids listed in FIG.
2 are available from Sigma-Aldrich.
2. Elmiric Acids Including Non-Mammalian Fatty Acids
[0045] In another aspect, an elmiric acid has the structure of
Formula I, and R.sub.1 is the hydrocarbon chain (tail) of a
non-mammalian fatty acid, such as pentadecanoic acid, 15:0;
heptadecanoic acid, 17:0; nonadecanoic acid, 19:0; heneicosanoic
acid, 21:0; 9-trans-tetradecanoic acid, 14:1T;
10-trans-pentadecanoic acid, 15:1T; 9-trans-hexadecenoic acid,
16:1T; 10-heptadecenoic acid, 17:1; 10-trans-heptadecenoic acid,
17:1T; 7-trans-nonadecenoic acid, 19:1T; 10,13-nonadecadienoic
acid, 19:2; 11-trans-eicosenoic acid, or 20:1T; 12-heneicosenoic
acid, 21:1. Exemplary non-mammalian fatty acids are listed in FIG.
1.
[0046] In some embodiments of this aspect, R.sub.3 and R.sub.4 are,
e.g., H and R.sub.2 is the side chain of a D- or L-isomer of an
amino acid such as alanine, valine, leucine, isoleucine, serine,
threonine, methionine, phenylalanine, tyrosine, lysine, aspartic
acid, glutamic acid, asparagine, or glutamine. In other embodiments
of this aspect, R.sub.2, R.sub.3, and R.sub.4 are H, thereby
forming a glycine conjugate.
[0047] In other embodiments, R.sub.4 is, e.g., H, and R.sub.2 and
R.sub.3 together form the cyclic side chain of an amino acid analog
that can be 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, or 1-amino-cyclohexane
carboxylic acid. In other embodiments, R.sub.2 and R.sub.3
represent the two methyl side chains of 2-aminoisobutyric acid. In
both of these embodiments where R.sub.2 and R.sub.3 are
substituents of an amino acid analog depicted in FIG. 3, the
alpha-carbon of Formula I is the carbon marked by an arrow in FIG.
3. The "R" in FIG. 3 denotes the amino group that can be used to
form an amide linkage to a fatty acid molecule, thereby forming an
N-fatty acid-amino acid conjugate.
[0048] In still other embodiments, R.sub.3 and R.sub.4 are, e.g.,
H, and R.sub.2 is the side chain of a phenyl-glycine or a
phenyl-glycine derivative, such that R.sub.2 has the general
structure of Formula III, and X can be, e.g., H, OH,
CH.sub.2NH.sub.2, or SO.sub.3.
[0049] In yet other embodiments, R.sub.3 and R.sub.4 are, e.g., H,
and R.sub.2 is the side chain of a phenylalanine derivative, such
that R.sub.2 has the general structure of Formula IV, wherein the
set of substituents corresponding to X, Y, and Z, can independently
be, e.g., H, OH, OCH.sub.3, F, Cl, I, CH.sub.3, C.sub.2H.sub.5,
NH--CO--CH.sub.3, SH, NH.sub.2, CN, CH.sub.2NH.sub.2, COOH, CHO,
NO.sub.2, CONH.sub.2, COCH.sub.3, or CH.sub.2OH. In specific
examples, X, Y, and Z (X, Y, Z), respectively, can be: (H, OH, H);
(H, OCH.sub.3, H); (H, H, OH); (H, H, OCH.sub.3); (1, H, H);
(CH.sub.3, H, H); (NH--CO--CH.sub.3, H, H); (SH, H, H); (NH.sub.2,
H, H); (Cl, H, H); (CN, H, H); (CH.sub.2NH.sub.2, H, H); (COOH, H,
H); (NO.sub.2, H, H); (CHO, H, H); (C.sub.2H.sub.5, H, H);
(i-C.sub.3H.sub.7, H, H); (OCH.sub.3, H, H); (CONH.sub.2, H, H);
(COCH.sub.3, H, H); (H, NO.sub.2, H); (F, H, H); (H, NH.sub.2, H),
and (CH.sub.2OH, H, H). Note that in the immediately preceding
group of substituent sets, each set of substituents marked off by
parenthesis is arranged in the following manner (X substituent, Y
substituent, and Z substituent), consistent with the phenylalanine
derivatives shown in FIG. 5.
[0050] In certain other embodiments, R.sub.3 is, e.g., H, and
R.sub.2 and R.sub.4 together form a proline or the structure of any
one of Formulas V, VI, and VII and the arrow denotes the
.alpha.-carbon of Formula I. The R.sub.I hydrocarbon chain of a
fatty acid is amide linked to the nitrogen molecule in the ring
structure of Formulas V, VI, and VII, thereby forming an N-fatty
acid-amino acid conjugate. In embodiments where R.sub.2 and R.sub.4
form the ring structure of Formula V, X can be, e.g., CN, CHO,
CH.sub.2OH, CH.sub.2NH.sub.2, COOH, CH.sub.2CN, NH.sub.2, or
phenyl.
3. N-Fatty Acid-Dipeptide Amino Acid Conjugates
[0051] In another aspect, an elmiric acid includes a dipeptide
conjugated to a fatty acid. These conjugates have the following
general formula (Formula II):
##STR00007##
(R.sub.2 and R.sub.3) and (R.sub.4 and R.sub.5) are substituents of
two amino acids that include the depicted alpha carbons, thereby
creating a dipeptide that is amide linked to a fatty acid. The
dipeptide can consist of two natural amino acids, two amino acid
analogs, or one natural amino acid and one amino acid analog. In
some embodiments, (R.sub.2 and R.sub.3) and/or (R.sub.4 and
R.sub.5) are substituents of a D-amino acid, an L-amino acid, or an
amino acid analog. In some embodiments, R.sub.2 and R.sub.3
together form the cyclic side chain of an amino acid analog with a
cyclic side chain. In some embodiments, R.sub.4 and R.sub.5
together form the cyclic side chain of an amino acid analog with a
cyclic side chain. In some embodiments, R.sub.2 and R.sub.3 are the
two methyl groups of aminoisobutyric acid. In some embodiments,
R.sub.4 and R.sub.5 are the two methyl groups of aminoisobutyric
acid. Exemplary N-fatty acid-dipeptide amino acid conjugates
include dipeptides such as glycine-2-aminoisobutyric acid,
alanine-2-aminoisobutyric acid, glycine-1-amino-cyclopentane
carboxylic acid, alanine-1-amino-cyclopentane carboxylic acid,
glycine-glycine-COOH, glycine-alanine-COOH, alanine-glycine-COOH,
and alanine-alanine-COOH.
[0052] In some embodiments of this conjugate, R.sub.1 can be the
hydrocarbon chain (tail) of a mammalian fatty acid such as myristic
acid 14:0; palmitic acid, 16:0; stearic acid, 18:0, oleic acid,
18:1; linoleic acid, 18:2; linolenic acid, 18:3; eicosatrienoic
acid, 20:3; arachidonic acid, 20:4; eicosapentenoic acid, 20:5;
docosatetraenoic acid, 22:4.
[0053] In other embodiments, R.sub.1 can be the hydrocarbon chain
(tail) of an non-mammalian fatty such as pentadecanoic acid, 15:0;
heptadecanoic acid, 17:0; nonadecanoic acid, 19:0; heneicosanoic
acid, 21:0; 9-trans-tetradecanoic acid, 14:1T;
10-trans-pentadecanoic acid, 15:1T; 9-trans-hexadecenoic acid,
16:1T; 10-heptadecenoic acid, 17:1; 10-trans-heptadecenoic acid,
17:1T; 7-trans-nonadecenoic acid, 19:1T; 10,13-nonadecadienoic
acid, 19:2; 11-trans-eicosenoic acid, 20:1T; and 12-heneicosenoic
acid, 21:1.
4. J.sub.2 Prostanoid-Amino Acid Conjugates
[0054] In another aspect, a J acid has the structure of Formula I,
and R.sub.1 is the non-carboxyl portion (tail) of a J.sub.2
prostanoid, e.g., prostaglandin J.sub.2,
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2,
.DELTA..sup.12-prostaglandin J.sub.2, or
9,10-dihydro-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2
(CAY10410). Exemplary J.sub.2 prostanoids are depicted in FIG. 9,
all of which are available from Cayman Chemical Company (Aim Arbor,
Mich.).
[0055] In some embodiments of this aspect, R.sub.3 and R.sub.4 are,
e.g., H and R.sub.2 is the side chain of a D- or L-isomer of an
amino acid such as alanine, valine, leucine, isoleucine, serine,
threonine, methionine, phenylalanine, tyrosine, lysine, aspartic
acid, glutamic acid, asparagine, or glutamine. In other embodiments
of this aspect, R.sub.2, R.sub.3, and R.sub.4 are H, thereby
forming a glycine conjugate.
[0056] In other embodiments, R.sub.4 is, e.g., H, and R.sub.2 and
R.sub.3 together form the cyclic side chain of an amino acid analog
that can be 1-amino-cyclopropane carboxylic acid,
1-amino-cyclopentane carboxylic acid, or 1-amino-cyclohexane
carboxylic acid. In other embodiments, R.sub.2 and R.sub.3
represent the two methyl side chains of 2-aminoisobutyric acid.
[0057] In both of these embodiments where R.sub.2 and R.sub.3 are
substituents of an amino acid analog depicted in FIG. 3, the
alpha-carbon of Formula I is the carbon marked by an arrow in FIG.
3. The "R" in FIG. 3 denotes the amino group that can be used to
form an amide linkage to a fatty acid molecule, thereby forming an
N-fatty acid-amino acid conjugate.
[0058] In still other embodiments, R.sub.3 and R.sub.4 are, e.g.,
H, and R.sub.2 is the side chain of a phenyl-glycine or a
phenyl-glycine derivative, such that R.sub.2 has the general
structure of Formula III, and X can be, e.g., H, OH,
CH.sub.2NH.sub.2, or SO.sub.3.
[0059] In yet other embodiments, R.sub.3 and R.sub.4 are, e.g., H,
and R.sub.2 is the side chain of a phenylalanine derivative, such
that R.sub.2 has the general structure of Formula IV, wherein the
set of substituents corresponding to X, Y, and Z, can independently
be, e.g., H, OH, OCH.sub.3, F, Cl, I, CH.sub.3, C.sub.2H.sub.5,
i-C.sub.3H.sub.7, NH--CO--CH.sub.3, SH, NH.sub.2, CN,
CH.sub.2NH.sub.2, COOH, CHO, NO.sub.2, CONH.sub.2, COCH.sub.3, or
CH.sub.2OH. In specific examples, X, Y, and Z (X, Y, Z),
respectively, can be: (H, OH, H); (H, OCH.sub.3, H); (H, H, OH);
(H, H, OCH.sub.3); (I, H, H); (CH.sub.3, H, H); (NH--CO--CH.sub.3,
H, H); (SH, H, H); (NH.sub.2, H, H); (Cl, H, H); (CN, H, H);
(CH.sub.2NH.sub.2, H, H); (COOH, H, H); (NO.sub.2, H, H); (CHO, H,
H); (C.sub.2H.sub.5, H, H); (i-C.sub.3H.sub.7, H, H); (OCH.sub.3,
H, H); (CONH.sub.2, H, H); (COCH.sub.3, H, H); (H, NO.sub.2, H);
(F, H, H); (H, NH.sub.2, H), and (CH.sub.2OH, H, H). Note that in
the immediately preceding group of substituent sets, each set of
substituents marked off by parenthesis is arranged in the following
manner (X substituent, Y substituent, and Z substituent),
consistent with the phenylalanine derivatives shown in FIG. 5.
[0060] In certain other embodiments, R.sub.3 is, e.g., H and
R.sub.2 and R.sub.4 together form the structure of proline or any
one of Formulas V, VI, and VII and the arrow denotes the
.alpha.-carbon of Formula I. The R.sub.1 hydrocarbon chain of a
fatty acid is amide linked to the nitrogen molecule in the ring
structure of Formulas V, VI, and VII, thereby forming an N-fatty
acid-amino acid conjugate. In embodiments where R.sub.2 and R.sub.4
form the ring structure of Formula V, X can be, e.g., CN, CHO,
CH.sub.2OH, CH.sub.2NH.sub.2, COOH, CH.sub.2CN, NH.sub.2, or
phenyl.
5. J.sub.2 Prostanoid-Dipeptide Amino Acid Conjugates
[0061] In another aspect, an elmiric acid includes a dipeptide
conjugated to a J.sub.2 prostanoid, e.g., prostaglandin
J.sub.2,15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2,
.DELTA..sup.12-prostaglandin J.sub.2, or
9,10-dihydro-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2
(CAY10410). These conjugates have the following general formula
(Formula II):
##STR00008##
(R.sub.2 and R.sub.3) and (R.sub.4 and R.sub.5) are substituents of
two amino acids that include the depicted alpha carbons, thereby
creating a dipeptide that is amide linked to a J.sub.2 prostanoid.
The dipeptide can consist of two natural amino acids, two amino
acid analogs, or one natural amino acid and one amino acid analog.
In some embodiments, (R.sub.2 and R.sub.3) and/or (R.sub.4 and
R.sub.5) are substituents of a D-amino acid, an L-amino acid, or an
amino acid analog. In some embodiments, R.sub.2 and R.sub.3
together form the cyclic side chain of an amino acid analog with a
cyclic side chain. In some embodiments, R.sub.4 and R.sub.5
together form the cyclic side chain of an amino acid analog with a
cyclic side chain. In some embodiments, R.sub.2 and R.sub.3 are the
two methyl groups of aminoisobutyric acid. In some embodiments,
R.sub.4 and R.sub.5 are the two methyl groups of aminoisobutyric
acid. Exemplary J.sub.2 prostanoid-dipeptide amino acid conjugates
include dipeptides such as glycine-2-aminoisobutyric acid,
alanine-2-aminoisobutyric acid, glycine-1-amino-cyclopentane
carboxylic acid, alanine-1-amino-cyclopentane carboxylic acid,
glycine-glycine-COOH, glycine-alanine-COOH, alanine-glycine-COOH,
and alanine-alanine-COOH.
Methods of Making Lipid-Amino Acid Conjugates
[0062] In the protocols that follow, "fatty acid" refers, e.g., to
any one of the fatty acids listed in FIG. 1, "J.sub.2 prostanoid"
refers, e.g., to any one of the compounds depicted in FIG. 9, and
amino acid refers, e.g., to any one of the amino acids listed in
FIGS. 2-6. As above, R.sub.1 refers to the non-carboxyl portion
(tail) of a fatty acid or J.sub.2 prostanoid, and R.sub.2 refers to
the side chain of an amino acid. Reaction conditions and
concentrations of reagents vary depending on the requirements of
the fatty acid or J.sub.2 prostanoid and amino acid groups used.
Various protocols can be used to prepare non-mammalian fatty
acid-amino acid conjugates. The protocols described below can be
scaled up or down in volume, and chemically equivalent reagents may
be substituted for the reagents indicated.
[0063] Amino acid methyl esters can be purchased from commercial
vendors, e.g., RSP, Amino Acid Analogues, Inc. Alternatively, amino
acid methyl esters can be synthesized by dissolving an amino acid
or an amino acid analog (.about.200 mg to .about.2 g) in methanol
saturated with HCl (.about.30 to .about.300 ml) and refluxed for
6-12 hours. The solvent is then removed under vacuum and the crude
product dissolved in ethyl acetate and partitioned with saturated
bicarbonate to remove traces of unreacted amino acid.
Protocol #1
[0064] The following protocol describes one method to prepare a
lipid-amino acid conjugate, e.g., an elmiric acid or J acid. See
FIG. 7 for a general scheme of the protocol. For example, the
protocol is suitable for the production of any of the following:
D-alanine, D-valine, D-leucine, D-isoleucine, D-phenylalanine,
D-asparagine, D-glutamine, and .gamma.-aminobutyric acid conjugates
of long-chain fatty acids. These long-chain fatty acids include
arachidonic, myristic, palmitic, stearic, oleic, linoleic,
eicosatrienoic, eicosapentenoic, and docosatetraenoic acids. The
protocol is also suitable for use with any fatty acid, J.sub.2
prostanoid, or amino acid group.
[0065] Generally the protocol involves the following steps. Prepare
a solution of 10 milliequivalents (mequivalents) of amino acid
methyl ester HCl in 5-10 ml methylene chloride containing 0.5-1.5
ml of triethylamine and cooling to 0.degree. C. A solution of 10
mequivalents of fatty acid chloride or J.sub.2 prostanoid chloride
in 2-5 ml methylene chloride is added to the amino acid ester
solution and allowed to react for a time sufficient to complete the
conjugation, e.g., for 60, 120, 180, or 240 minutes, at 0-4.degree.
C. An equal volume of water is added to terminate the reaction, and
the reaction is then extracted with ethyl acetate. The organic
layer is dried with sodium sulfate, filtered, and evaporated to
dryness under vacuum. The lipid-amino acid conjugate methyl ester
product is purified by silica gel column chromatography and is
eluted with 1.5% methanol in methylene chloride. Other protocols
can be used.
[0066] A solution of N-fatty acid or J.sub.2 prostanoid-amino acid
conjugate methyl ester (from .about.0.6 to .about.1.0 nmol) in
tetrahydrofuran (.about.2 to .about.3 ml) is treated with 1 M
aqueous lithium hydroxide (.about.0.5 to .about.1.0 ml). The
mixture is stirred for 45 minutes under nitrogen at room
temperature followed by evaporation under vacuum. The residue is
diluted with 10-20 ml of water, acidified to pH 3.0 with HCl and
extracted with ethyl acetate. The combined extracts are washed with
water, dried with sodium sulfate and evaporated under vacuum. The
elmiric acid or J acid product is purified using silica gel column
chromatography and eluted with methanol in methylene chloride.
Protocol #2
[0067] The following protocol describes an alternate method of
preparing a lipid-amino acid conjugate, e.g., an elmiric acid or J
acid. FIG. 7 also provides a general scheme for this protocol. A
fatty acid chloride or J.sub.2 prostanoid chloride in methylene
chloride is reacted with amino acid methyl ester in methylene
chloride containing 5% triethylamine for 2-8 hours at room
temperature. The mixture is then partitioned between ethyl acetate
and dilute HCl, washed, dried and evaporated to an oily residue.
This residue is dissolved in tetrahydrofuran and saponified by
stirring under nitrogen with LiOH for 4-10 hours at room
temperature. The product is diluted with water, acidified to pH 3.0
with HCl and extracted with ethyl acetate. The combined extracts
are washed with water, dried with sodium sulfate, evaporated under
vacuum, and purified by thin layer chromatography.
Protocol #3
[0068] The following protocol describes an alternate method of
preparing a lipid-amino acid conjugate, e.g., an elmiric acid or J
acid. See FIG. 8 for a general scheme of the protocol. 10-100 mg of
fatty acid or J.sub.2 prostanoid is added to a solution of
N-hydroxysuccinimide (NHS) (4-40 mg) in 5-50 ml of ethyl acetate,
followed by addition of 9-90 mg of dicyclohexylcarbodiimide. The
mixture is allowed to react for 12-36 hours at room temperature,
after which 10 mg of amino acid in a mixture of dioxane-KOH--NaHCO3
(2-20 ml) is added and reacted for a further 24-72 hours at
40.degree. C. The mixture is then acidified with HCl, extracted
with ethyl acetate and the product isolated by thin layer
chromatography.
Methods of Use
[0069] The lipid-amino acid conjugates disclosed herein, e.g.,
elmiric acids and J acids, can be used as regulators of the
peroxisome proliferator-activated receptor (PPAR) family member
PPAR.gamma.. One or more lipid-amino acid conjugates can be
screened in one of several peroxisome proliferator-activated
receptor (PPAR) activation assays (as described below) to determine
the PPAR.gamma. activation potency of the conjugate. One or more
elmiric acids or J acids can be used to treat a disorder that
involves PPAR.gamma. regulation, e.g., diabetes or a disorder of
lipid metabolism and glucose homeostasis. Elmiric acids or J acids
can also be co-administered to patients taking antiretroviral
medications to treat lipodystrophy and insulin resistance
associated with certain antiretroviral therapies.
[0070] The PPARs are transducer proteins belonging to the
steroid/thyroid/retinoid receptor superfamily. Three subtypes of
PPAR have been identified, designated as PPAR-alpha (PPAR-.alpha.),
PPAR-beta (PPAR-.beta.) or PPAR-delta (PPAR-.delta.), and
PPAR-gamma (PPAR-.gamma.). These receptors function as
activator-regulated transcription factors that control the
expression of target genes by binding to their responsive DNA
sequence as heterodimers with retinoid x receptor (RXR).
[0071] The PPAR.alpha. subtype has been cloned from Xenopus,
humans, mouse, and rat; the PPAR.beta. (or PPAR.delta.) subtype
from Xenopus, humans, and mouse; and the PPAR.gamma. subtype from
Xenopus, humans, and hamster. These subtypes are pharmacologically
distinct and differentially activated by various agents (Yu et al.,
Cell, 67:1251-1266, 1991). The following are corresponding Genbank
accession numbers: PPAR.alpha.(.delta.) (AF246303), PPAR.beta.
(AL022721), and PPAR.gamma. (AY157024). PPAR.gamma. exists as at
least two isotypes, PPAR.gamma.1 and PPAR.gamma.2. PPAR.gamma.2 is
expressed selectively in adipose tissue, whereas PPAR.gamma.1 is
expressed at lower levels in a variety of other rodent and human
tissues (Spiegelman, Diabetes, 47:507-514, 1998).
[0072] PPAR.gamma. is a pharmacologically important member of the
nuclear receptor superfamily (Houseknecht et al., Domest. Anim.
Endocrinol., 22:1-23, 2002). It plays important roles in a diverse
array of biological processes including lipid metabolism, glucose
homeostasis, and adipocyte differentiation. The crystal structure
of the PPAR.gamma. ligand-binding domain reveals a large
hydrophobic cavity for ligand binding (Uppenberg et al., J. Biol.
Chem., 273:31108-12, 1998; and Xu et al., Proc. Nat'l. Acad. Sci.
USA, 98:13919-24, 2001). Indeed, PPAR.gamma. binds to a wide range
of synthetic and naturally occurring substances, including the
antidiabetic drugs thiazolidinediones (TZDs) (Lehmann et al., J.
Biol. Chem., 270:12953-6, 1995; Willson et al., J. Med. Chem.,
39:665-8, 1996), the synthetic tyrosine analog GW347845 (Cobb et
al., J. Med. Chem., 41:5055-5069, 1998), polyunsaturated fatty
acids (Kliewer et al., Proc. Nat'l. Acad. Sci. USA, 94:4318-23,
1997), metabolites of arachidonic acid including
15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2 and other J.sub.2
prostanoids (Forman et al., Cell, 83:803-12, 1995; Kliewer et al.,
Cell, 83:813-9, 1995), NSAIDs (Lehmann et al., J. Biol. Chem.,
272:3406-10, 1997), and compounds of oxidized low-density
lipoprotein, such as 13-hydroxyoctadecadienoic acid (13-HODE) and
15-hydroxyeicosatraenoic acid (15-HETE) (Nagy et al., Cell,
93:229-40, 1998).
[0073] Several of these PPAR.gamma. ligands exhibit
anti-inflammatory activity in vivo (Kawahito et al., J. Clin.
Invest., 106:189-97, 2000; Naito et al., Aliment Pharmacol. Ther.,
15:865-73, 2001), and activation of PPAR.gamma. is directly linked
to anti-inflammatory (Jiang et al., Nature, 391:82-6, 1998), and
antitumor processes (Patel et al., Curr. Biol., 11:764-8, 2001).
Accordingly, activation of PPAR.gamma. inhibits the expression of
cytokines, such as interleukin (IL)-1.beta., tumor necrosis factor
.alpha. (TNF.alpha.), and nitric oxide (NO) at both the protein and
transcription levels (Jiang et al., Nature, 391:82-6, 1998; Ricote
et al., Nature, 391:79-82, 1998). PPAR.gamma. is expressed in
adipose tissue, skeletal muscle, adrenal gland, colonic epithelium,
heart, pancreas, and liver (Mukherjee et al., J. Biol. Chem.,
272:8071-6, 1997; Sarraf et al., Nat. Med., 4:1046-52, 1998). It is
also expressed in immune system related cells such as splenocytes
(Clark et al., J. Immunol., 164:1364-71, 2000; Kliewer et al.,
Proc. Natl. Acad. Sci. USA, 91:7355-9, 1994), synoviocytes (Ji et
al., J. Autoimmun., 17:215-21, 2001; Kawhito et al., J. Clin.
Invest., 106:189-97, 2000; Simonin et al., Am. J. Physiol. Cell
Physiol., 282:C125-33, 2002), helper T cells (Clark et al., J.
Immunol., 164:1364-71, 2000), and activated monocytes and
macrophages (Jiang et al., Nature, 391:82-6, 1998; Kawahito et al.,
J. Clin. Invest., 106:189-97, 2000; Ricote et al., Nature,
391:79-82, 1998) suggesting that PPAR.gamma. has a direct role in
modulating inflammation in addition to its role in lipid metabolism
and glucose homeostasis.
[0074] PPAR.gamma. modulates the expression of genes involved in
the regulation of growth and differentiation in a variety of cell
types that express the receptor. PPAR.gamma. has been shown to be
expressed in an adipose tissue-specific manner. Its expression is
induced early during the course of differentiation of several
preadipocyte cell lines. PPAR.gamma. plays a role in the adipogenic
signaling cascade and also regulates the ob/leptin gene which is
involved in regulating energy homeostasis.
[0075] In one aspect, the new methods and compositions can be used
to treat autoimmune diseases or disorders involving PPAR.gamma. by
using a PPAR.gamma. regulator that is or includes a lipid-amino
acid conjugate, e.g., an N-fatty acid-amino acid conjugate or
J.sub.2 prostanoid-amino acid conjugate. In general, the methods
involve providing an amount of a PPAR.gamma. regulator sufficient
to modulate the expression of genes encoding proteins involved in
autoimmune diseases, such as diabetes mellitus, inflammatory
cytokines such as tumor necrosis factor-.alpha. (TNF .alpha.), or
inhibition of the production of inflammatory cytokines such as
IL-1.alpha., IL-1.beta., IL-2, IL-6, IL-8, and TNF-.alpha., or the
inhibition of their biological activity. While the PPAR.gamma.
regulator can be utilized alone, the therapy can also be
administered in combination with other therapeutics such as
existing naturally occurring or synthetic activators, steroidal and
non-steroidal anti-inflammatory agents, existing therapies for
diabetes, and agents that modulate apoptosis in pathological
cells.
[0076] In one embodiment, the cells to be treated are those
involved in inflammatory disorders. These include inflammatory
(immune system) cells (e.g., T lymphocytes and macrophages),
PPAR.gamma. expressing cells and tissues involved in the
pathogenesis of inflammatory diseases, including all forms of
uveitis and uveoretinitis, iritis, cyclitis, choroiditis,
chorioretinitis, vitritis, keratitis and conjunctivitis, systemic
autoimmune disorders (e.g., type 1 diabetes mellitus, Sjogren's
syndrome, and hyperthyroidism), and collagen vascular diseases
(e.g., ankylosing spondylitis, rheumatoid arthritis, lupus
erythematosus, Reiter syndrome, Bechet disease, ulcerative colitis,
Crohn's disease, and Wegener's granulomatosis).
[0077] In another embodiment, the cells to be treated are those
involved in autoimmune disorders, such as the pancreatic
.beta.-cells of a subject with diabetes.
1. PPAR.gamma. Activation Assays
[0078] The PPAR.gamma. activation potency of a lipid-amino acid
conjugate described herein can be tested in vitro using one or both
of the following assays.
[0079] a) The Oil Red O assay is an adipocyte differentiation assay
that can be performed as described by Mukherjee et al., J. Biol.
Chem., 272:8071-6, 1997. Oil Red O
(1-[[4-[(dimethylphenyl)azo]dimethylphenyl]azo]-2-naphthol) is a
highly lipophilic dye substance that is used extensively in
histology to visualize areas rich in neutral lipids such as
triglycerides and cholesteryl esters. It produces an intense red
color due to its light absorbtion characteristics;
.lamda..sub.max=518 nm. PPAR-.gamma. agonist treatment of intact
cells in culture often results in an accumulation of neutral lipids
that are sometimes visible by light microscopy and can be stained
black with osmium tetroxide and red with Oil Red O. This has been
considered as a strong indication of PPAR-.gamma. activation (See,
e.g., Lenhard et al., Antiviral Res., 47:121-129, 2000; Landsberg
et al., Proc. Nat'l. Acad. Sci. USA, 100:2456-2461, 2003; Starkey
et al., J. Clin. Endocrinol. Metab., 88:55-59, 2003; Tang et al.,
Proc. Nat'l. Acad. Sci. USA, 100:850-855, 2003).
[0080] Generally, the Oil Red assay involves culturing cells, such
as 3T3 L1 fibroblasts (American Type Culture Collection), to
confluence in DMEM media supplemented with 10% calf serum. In the
assay, GW347845 is a potent PPAR.gamma. specific ligand that can be
used as a positive control (Cobb et al., J. Med. Chem.,
41:5055-5069, 1998), while vehicle treated cells are used as a
baseline control. Two days after reaching confluence cells are
contacted with: (i) 1-100 .mu.g of a lipid-amino acid conjugate
with vehicle (e.g., 0.1% DMSO), (ii) GW347845 with vehicle, or
(iii) vehicle alone. Treatments are administered in the presence of
10 mg/ml insulin every other day. After 3-14 days of treatment with
the lipid acid-amino acid conjugate and 7 days with GW347845 at
confluence, cells are fixed and stained with Oil Red O (Sigma).
[0081] Oil Red O staining is performed as follows: (1) media is
removed, and 0.5 ml formalin is added to the cells, (2) after 1
hour, formalin is removed and cells are washed 2.times. with water,
(3) 0.1 ml oil red staining solution is added for 1 hour at room
temperature, (4) stained cells are washed with water, thoroughly
drained, and then dried at 37.degree. C. for 1 hour, (5) dye is
extracted with 1.00 ml of isopropyl alcohol on shaker for 15
minutes, and 6) absorbance at 510 nm is measured.
[0082] b) PPAR.gamma. activation potency can also be tested using a
"lipid incorporation" assay that can be performed as follows.
Monolayers of cells, e.g., C6 rat glioma cells, are prepared in
24-well culture dishes. Carboxy-labeled [.sup.14C]oleic acid
(150,000 dpm/well) (obtained from American Radio Chemicals (ARC)
St. Louis, Mo.; specific activity: 55 mCi/mmol) is added to each
monolayer and incubated for 2 hours at 4.degree. C. Cells are then
treated with an N-fatty acid-amino acid conjugate or J.sub.2
prostanoid-amino acid conjugate in vehicle, e.g., 10 .mu.l of DMSO
to 1 ml of the culture medium covering each monolayer. Treatment is
continued for 48 hours except where indicated otherwise, at which
time, medium is removed and discarded, since preliminary
examination showed that little if any radiolabeled lipid is
present. After washing with PBS (1 ml), the cellular lipids are
extracted for 0.5 hour with 0.5 ml of 95% ethanol at room
temperature. Treatments can be performed in quadruplicate;
vehicle-treated cells serve as a control.
[0083] Prior to evaporation under vacuum, [.sup.14C]cholesterol
(50,000 dpm) (from ARC; specific activity: 50 mCi/mmol) is added as
a recovery marker. The sample residues are then dissolved in 30
.mu.l of methanol containing 10 .mu.g each of steroyl-arachidonoyl
diglyceride, triolein, and phosphatidylcholine (PC) and applied to
0.25-mm silica gel thin layer plates. A first elution is performed
with dichloromethane:acetone (90:10) for the analysis of neutral
lipids. The R.sub.f values of the standards are: PC=0,
cholesterol=0.38, Diacylglyceride (DG)=0.64, and Triacylglyceride
(TG)=0.81. Following the quantitation of the neutral lipids, a
second elution is carried out using chloroform:methanol:acetic
acid:water (50:25:8:2) as the eluent for the analysis of
phospholipid. The Rf value of PC is 0.33; DG and TG moved to the
solvent front. All standards can be detected by exposure to iodine
vapor.
[0084] Zones of radioactivity are detected by exposure of TLC
plates to x-ray film for 48 hours. A computerized image of the film
can be generated using the FLUOR-S.TM. System (Bio-Rad).
Radioactivity on the chromatograms can be quantified using NIH
Image software. Peak height values of the display are used since
the zones all showed narrow sharp peaks. These are adjusted for
recovery using the individual cholesterol standard values for each
zone. The values obtained are then divided by the numbers of cells
in each well, and the results are expressed as an index/million
cells.
2. Use of Lipid-Amino Acid Conjugates to Treat Diabetes
[0085] Some lipid-amino acid conjugates, e.g., elmiric acids and J
acids, can reduce blood glucose and triglyceride levels and are
accordingly useful for the treatment of disorders such as diabetes
and obesity.
[0086] In one embodiment, one or more elmiric acids or J acids are
used to regulate PPAR.gamma. in a treatment for an autoimmune
disorder such as diabetes. Diabetes is a multifactorial disease
that occurs through the failure and/or destruction of the
pancreatic .beta.-cell. There is a large body of evidence in
support of the idea that inflammatory cytokines have cytotoxic
effects on islet .beta.-cells (Rabinovitch, J. Clin. Endocrinol.
Metab., 71:152-6, 1990) and that this cytotoxicity plays a part in
.beta.-cell destruction in insulin-dependent diabetes mellitus
(IDDM).
[0087] Obesity-linked non-insulin-dependent diabetes mellitus
(NIDDM) is preceded by years of insulin resistance, during which
normal blood glucose levels are maintained through effective
compensation by pancreatic .beta.-cells. In approximately 20% of
obese individuals, the compensation wanes, hyperglycemia appears,
and overt NIDDM is diagnosed. The depressed .beta.-cell function is
thought to be due to excess free fatty acids released from
adipocytes in obesity (Campbell et al., Am. J. Physiol.,
266:E600-5., 1994; DeFronzo, Diabetes Metab. Rev., 4:727-47, 1988)
acting to initially stimulate, but ultimately impair, the function
of .beta.-cells, and thus limit their compensatory capability.
Thus, impaired .beta.-cell function is a characteristic of both
IDDM and NIDDM.
[0088] Elmiric acids and J acids are useful for the modification,
treatment, and/or prophylaxis of insulin resistance (Type II
diabetes), impaired glucose tolerance, dyslipidemia, disorders
related to Syndrome X such as hypertension, obesity, insulin
resistance, hyperglycemia, atherosclerosis, hyperlipidemia,
coronary artery disease, and other cardiovascular disorders
associated with diabetes. Other disorders associated with diabetes
include the anti-apoptotic effect of PPAR.gamma. regulators that
serves to protect cells from premature death and promote their
survival, as in degenerative and dystrophic diseases, e.g., retinal
neural and glial cells in diabetic retinopathy and both "wet"
(exudative) and "dry" (aereolar) age-related macular
degeneration.
[0089] Before administration to a subject, an elmiric acid or J
acid can be tested for biological activity (i.e., ability to
decrease cell proliferation) both in vitro or in vivo. In vitro
testing can be performed as described in the examples described
herein. In vivo animal models for diabetes are also well known in
the art, for example, obese mice (ob/ob), and diabetic (db/db) mice
from the Jackson Laboratories (Bar Harbor, Me.) (see, e.g., Collins
et al., J. Biol. Chem., 271:9437-9440, 1996; Darling, Curr. Opin.
Genet. Dev., 6:289-294, 1996; Andersson, Ann. Med., 28:5-7, 1996;
Van Heek et al., J. Clin. Invest., 99:385-390, 1997). These animal
models can be used to assess the effect of the N-fatty acid-amino
acid conjugate or J.sub.2 prostanoid-amino acid conjugate on
diabetes and obesity.
3. Use of Lipid-Amino Acid Conjugates to Treat Lipid Metabolism and
Glucose Homeostasis Disorders
[0090] In another embodiment, one or more lipid-amino acid
conjugates, e.g., elmiric acids or J acids, are administered to a
subject to regulate PPAR.gamma. and thereby treat or modify a
disorder related to lipid metabolism and glucose homeostasis.
[0091] Adipose tissue plays a central role in lipid homeostasis and
the maintenance of energy balance in vertebrates. Adipocytes store
energy in the form of triglycerides during periods of nutritional
affluence and release it in the form of free fatty acids at times
of nutritional deprivation. The development of white adipose tissue
is the result of a continuous differentiation process throughout
life. Much evidence points to the central role of PPAR.gamma.
activation in initiating and regulating this cell differentiation.
Several highly specialized proteins are induced during adipocyte
differentiation, most of them being involved in lipid storage and
metabolism. Accordingly, some elmiric acids and J acids that
regulate PPAR.gamma. can be used to regulate lipid metabolism and
glucose homeostasis by regulating adipocyte tissue
differentiation.
[0092] The exact link from activation of PPAR.gamma. to changes in
glucose metabolism, most notably a decrease in insulin resistance
in muscle, has not yet been clarified. While not intending to be
bound by theory, a possible link is via free fatty acids.
Activation of PPAR.gamma. induces lipoprotein lipase (LPL), fatty
acid transport protein (FATP) and acyl-coA synthetase (ACS) in
adipose tissue but not in muscle tissue. This, in turn, reduces the
concentration of free fatty acids in plasma dramatically, and due
to substrate competition at the cellular level, skeletal muscle and
other tissues with high metabolic rates eventually switch from
fatty acid oxidation to glucose oxidation with decreased insulin
resistance as a consequence. PPAR.gamma. is involved in stimulating
.beta.-oxidation of fatty acids. Accordingly, some conjugates that
regulate PPAR.gamma. can be used to regulate insulin resistance by
regulating fatty acid concentration in plasma.
4. Use of Lipid-Amino Acid Conjugates to Treat Inflammation
Involving PPAR.gamma.
[0093] In another embodiment, one or more lipid-amino acid
conjugates, e.g., elmiric acids or J acids, that activate
PPAR.gamma. activity can be used to treat disorders related to
undesirable inflammatory responses that are inhibited by
PPAR.gamma. activation. Thus, an elmiric acid or J acid can be used
for the treatment of diseases including, but not limited to,
immunologically-mediated inflammatory diseases such as rheumatoid
arthritis, systemic lupus erythematosus, psoriasis, eczema,
multiple sclerosis, diabetes, and thyroiditis. In addition, the
present compounds can modulate bone formation/resorption and are
useful in the treatment of conditions including, but not limited
to, ankylosing spondylitis, gout, arthritis associated with gout,
osteoarthritis, and osteoporosis.
[0094] Psoriasis is a chronic skin disease of scaling and
inflammation. Psoriasis occurs when skin cells quickly rise from
their origin below the surface of the skin and pile up on the
surface before they have a chance to mature. Typically this
movement (also called turnover) takes about a month, but in
psoriasis it may occur in only a few days. In its typical form,
psoriasis results in patches of thick, inflamed skin covered with
silvery scales. These patches, which are sometimes referred to as
plaques, usually itch or feel sore. They most often occur on the
elbows, knees, other parts of the legs, scalp, lower back, face,
palms, and soles of the feet, but they can occur on skin anywhere
on the body. Diagnosis of psoriasis is based primarily on these
characteristic symptoms. A skin biopsy can be useful in diagnosis.
Psoriatic arthritis occurs in some patients with psoriasis and can
often affect the joints at the ends of the fingers and toes. Back
pain may occur if the spine is involved. Lipid-amino acid
conjugates that activate PPAR.gamma. activity can be useful in
treating, preventing, or alleviating psoriasis or one or more
symptoms of psoriasis or psoriatic arthritis, e.g., in topical
pharmaceutical compositions.
[0095] Rheumatoid arthritis is an autoimmune inflammatory disease
that causes pain, swelling, stiffness, and loss of function in the
joints. Rheumatoid arthritis often presents in a symmetrical
pattern. The disease can affect the wrist and finger joints closest
to the hand, as well as other parts of the body. In addition,
patients with rheumatoid arthritis may have fatigue, occasional
fevers, and a general malaise. Positive factors for diagnosis of
rheumatoid arthritis include the "rheumatoid factor" blood antibody
and citrulline antibody. Lipid-amino acid conjugates that activate
PPAR.gamma. activity can be useful in treating, preventing, or
alleviating rheumatoid arthritis or one or more symptoms of
rheumatoid arthritis, e.g., in topical or systemic pharmaceutical
compositions.
5. Use of Lipid-Amino Acid Conjugates in Antiretroviral
Therapies
[0096] In still another embodiment, one or more lipid-amino acid
conjugates, e.g., elmiric acids or J acids, are used in conjunction
with antiretroviral therapies, e.g., anti-HIV therapies. The
increased use of potent antiretroviral therapies, such as the
protease inhibitor cocktails administered to patients infected with
HIV, has led to an increase in the complications associated with
antiretroviral therapies. Complications include insulin resistance
and lipodystrophy.
[0097] Lipodystrophy involves adverse changes in lipid metabolism
and fat redistribution. Small molecules that activate PPAR.gamma.
have been administered to patients with congenital lipodystrophy,
and these molecules reportedly stimulated adipogenesis and improved
insulin sensitivity. See, Arioglu et al., Ann. Intern. Med.,
133:263-74, 2000. On this basis, PPAR.gamma. activators such as
fibrates and thiazolidinediones are also being studied as adjuvants
for HIV protease inhibitor drugs to reduce associated
complications, such as lipodystrophy and insulin resistance, see,
e.g., Hadigan et al., Ann Intern Med., 140:786-794, 2004.
[0098] Lipid-amino acid conjugates that activate PPAR.gamma. can
therefore be administered as adjuvants to antiretroviral therapies
to reduce associated complications. For example, an effective dose
of one or more elmiric acids or J acids can be co-administered with
anti-HIV protease inhibitor cocktail to patients in need of
anti-HIV treatment. Co-administration of elmiric acids or J acids
can suppress side effects associated with anti-HIV treatments, such
as lipodystrophy and insulin resistance.
Pharmaceutical Compositions
[0099] Pharmaceutical compositions containing one or more
lipid-amino acid conjugates, e.g., elmiric acids or J acids, may be
prepared by conventional techniques (e.g., as described in
Remington: The Science and Practise of Pharmacy, 19th Ed., 1995).
The compositions may appear in conventional forms, such as
capsules, tablets, aerosols, solutions, suspensions, or topical
applications.
[0100] Typical compositions include an elmiric acid or J acid
associated with a pharmaceutically acceptable excipient which may
be a carrier or a diluent or be diluted by a carrier, or enclosed
within a carrier which can be in the form of a capsule, sachet,
paper, or other container. In making the compositions, conventional
techniques for the preparation of pharmaceutical compositions may
be used. For example, the compound of interest will typically be
mixed with a carrier, or diluted by a carrier, or enclosed within a
carrier, which may be in the form of an ampule, capsule, sachet,
paper, or other container. When the carrier serves as a diluent, it
may be solid, semi-solid, or liquid material, which acts as a
vehicle, excipient, or medium for the active compound. The compound
of interest can be adsorbed on a granular solid container for
example in a sachet. Some examples of suitable carriers are water,
salt solutions, alcohols, polyethylene glycols,
polyhydroxyethoxylated castor oil, peanut oil, olive oil, lactose,
terra alba, sucrose, cyclodextrin, amylose, magnesium stearate,
talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl
ethers of cellulose, silicic acid, fatty acids, fatty acid amines,
fatty acid monoglycerides and diglycerides, pentaerythritol fatty
acid esters, polyoxyethylene, hydroxymethylcellulose, and
polyvinylpyrrolidone. Similarly, the carrier or diluent may include
any sustained release material known in the art, such as glyceryl
monostearate or glyceryl distearate, alone or mixed with a wax. The
formulations may also include wetting agents, emulsifying and
suspending agents, preserving agents, sweetening agents or
flavoring agents. The formulations of the invention may be
formulated so as to provide quick, sustained, or delayed release of
the active ingredient after administration to the patient by
employing procedures well known in the art.
[0101] The pharmaceutical compositions can be sterilized and mixed,
if desired, with auxiliary agents, emulsifiers, salt for
influencing osmotic pressure, buffers and/or coloring substances
and the like, which do not deleteriously react with the active
compounds.
[0102] The route of administration may be any route that
effectively transports the lipid-amino acid conjugate to the
appropriate or desired site of action, such as oral, nasal,
pulmonary, transdermal, or parenteral, e.g., rectal, depot,
subcutaneous, intravenous, intraurethral, intramuscular,
intranasal, ophthalmic solution or an ointment, typically the oral
route.
[0103] For nasal administration, the preparation may contain the
elmiric acid or J acid dissolved or suspended in a liquid carrier,
in particular an aqueous carrier, for aerosol application. The
carrier may contain additives such as solubilizing agents, e.g.,
propylene glycol, surfactants, absorption enhancers such as
lecithin (phosphatidylcholine) or cyclodextrin, or preservatives
such as parabens.
[0104] To prepare topical formulations, the elmiric acid or J acid
is mixed into a dermatological vehicle as is known in the art. Such
topical pharmaceutical compositions can exist in many forms, e.g.,
in the form of a solution, cream, ointment, gel, lotion, shampoo,
or aerosol formulation adapted for application to the skin. The
weight percent of the active ingredient in the composition useful
in the methods described herein typically ranges from 0.01% to 10%,
e.g., 0.01% to 1%, 0.1% to 10%, 0.01% to 1%, 1% to 5%, or 5% to 10%
(based on the total weight of the composition) in admixture with a
pharmaceutically acceptable carrier. A wide variety of carrier
materials can be employed in the compositions described herein such
as alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E
oils, mineral oils, and polyethylene glycols. The compositions can
include dimethylsulfoxide (DMSO) or other permeabilizing agents.
Other additives, e.g., preservatives, fragrance, sunscreen, or
other cosmetic ingredients, can be present in the composition.
[0105] For ophthalmic applications, the elmiric acid or J acid is
formulated into solutions, suspensions, and ointments appropriate
for use in the eye. The concentrations are usually as discussed
above for local preparations. For ophthalmic formulations (see
Mitra (ed.), Ophthalmic Drug Delivery Systems, Marcel Dekker, Inc.,
New York, N.Y., 1993 and also Havener, W. H., Ocular Pharmacology,
C.V. Mosby Co., St. Louis, 1983).
[0106] For oral administration, either solid or fluid unit dosage
forms can be prepared. For preparing solid compositions such as
tablets, an elmiric acid or J acid is mixed into formulations with
conventional ingredients such as talc, magnesium stearate,
dicalcium phosphate, magnesium aluminum silicate, calcium sulfate,
starch, lactose, acacia, methylcellulose, and functionally similar
materials as pharmaceutical diluents or carriers.
[0107] Capsules are prepared by mixing the elmiric acid or J acid
with an inert pharmaceutical diluent and filling the mixture into a
hard gelatin capsule of appropriate size. Soft gelatin capsules are
prepared by machine encapsulation of a slurry of the compound of
interest with an acceptable vegetable oil, light liquid petrolatum
or other inert oil. Fluid unit dosage forms for oral administration
such as syrups, elixirs and suspensions can be prepared. The water
soluble forms can be dissolved in an aqueous vehicle together with
sugar, aromatic flavoring agents and preservatives to form a syrup.
An elixir is prepared by using a hydroalcoholic (e.g., ethanol)
vehicle with suitable sweeteners such as sugar and saccharin,
together with an aromatic flavoring agent. Suspensions can be
prepared with an aqueous vehicle with the aid of a suspending agent
such as acacia, tragacanth, methylcellulose and the like.
[0108] Appropriate formulations for parenteral use are apparent to
the practitioner of ordinary skill, such as the use of suitable
injectable solutions or suspensions. The formulation, which is
sterile, is suitable for various topical or parenteral routes
including intra-dermal, intramuscular, intravascular, and
subcutaneous.
[0109] In addition to the elmiric acid or J acid, the compositions
may include, depending on the formulation and mode of delivery
desired, pharmaceutically-acceptable, non-toxic carriers or
diluents, which include vehicles commonly used to form
pharmaceutical compositions for animal or human administration. The
diluent is selected so as not to unduly affect the biological
activity of the combination. Examples of such diluents which are
especially useful for injectable formulations are water, the
various saline, organic or inorganic salt solutions, Ringer's
solution, dextrose solution, and Hank's solution. In addition, the
pharmaceutical composition or formulation may include additives
such as other carriers; adjuvants; or non-toxic, non-therapeutic,
non-immunogenic stabilizers and the like.
[0110] Furthermore, excipients can be included in the formulation.
Examples include cosolvents, surfactants, oils, humectants,
emollients, preservatives, stabilizers and antioxidants. Any
pharmacologically acceptable buffer may be used, e.g., tris or
phosphate buffers. Effective amounts of diluents, additives, and
excipients are those amounts which are effective to obtain a
pharmaceutically acceptable formulation in terms of solubility,
biological activity, etc.
[0111] The elmiric acid or J acid may be incorporated into
microspheres. The compound of interest can be loaded into albumin
microspheres that can be used as a dry powder for nasal
administration. Other materials suitable for the preparation of
microspheres include agar, alginate, chitosan, starch, hydroxyethyl
starch, ovalbumin, agarose, dextran, hyaluronic acid, gelatin,
collagen, and casein. The microspheres can be produced by various
processes known to the person skilled in the art such as a spray
drying process or an emulsification process. Microspheres are
typically less than 500 .mu.m in diameter, e.g., less than 200,
100, 50, 20, 10, 5, 1, 0.5, 0.1, 0.05, or 0.01 .mu.m. Microspheres
can be used in multiple methods of delivering lipid-amino acid
conjugates, including topical and transdermal delivery.
[0112] For example, albumin microspheres can be prepared by adding
rabbit serum albumin in phosphate buffer to olive oil with stirring
to produce a water in oil emulsion. Glutaraldehyde solution is then
added to the emulsion and the emulsion stirred to cross-link the
albumin. The microspheres can then be isolated by centrifugation,
the oil removed and the spheres washed, e.g., with petroleum ether
followed by ethanol. Finally, the microspheres can be sieved and
collected and dried by filtration.
[0113] Starch microspheres can be prepared by adding a warm aqueous
starch solution, e.g., of potato starch, to a heated solution of
polyethylene glycol in water with stirring to form an emulsion.
When the two-phase system has formed (with the starch solution as
to the inner phase) the mixture is then cooled to room temperature
under continued stirring whereupon the inner phase is converted
into gel particles. These particles are then filtered off at room
temperature and slurried in a solvent such as ethanol, after which
the particles are again filtered off and laid to dry in air.
[0114] The microspheres can be hardened by well known cross-linking
procedures such as heat treatment or by using chemical
cross-linking agents. Suitable agents include dialdehydes,
including glyoxal, malondialdehyde, succinicaldehyde, adipaldehyde,
glutaraldehyde and phthalaldehyde, diketones such as butadione,
epichlorohydrin, polyphosphate, and borate. Dialdehydes are used to
cross-link proteins such as albumin by interaction with amino
groups, and diketones form schiff bases with amino groups.
Epichlorohydrin activates compounds with nucleophiles such as amino
or hydroxyl to an epoxide derivative.
[0115] The term "unit dosage form" refers to physically discrete
units suitable as unitary dosages for subjects, e.g., human
subjects or mammalian subjects, e.g., dogs, cats, and rodents, each
unit containing a predetermined quantity of active material
calculated to produce the desired pharmaceutical effect in
association with the required pharmaceutical diluent, carrier or
vehicle. The specifications for the unit dosage forms of this
invention are dictated by and dependent on (a) the unique
characteristics of the active material and the particular effect to
be achieved and (b) the limitations inherent in the art of
compounding such an active material for use in humans and animals.
Examples of unit dosage forms are tablets, capsules, pills, powder
packets, wafers, suppositories, granules, cachets, teaspoonfuls,
tablespoonfuls, dropperfuls, ampoules, vials, aerosols with metered
discharges, segregated multiples of any of the foregoing, and other
forms as herein described. The compositions can be included in
kits, which can contain one or more unit dosage forms of the
composition and instructions for use to treat one or more of the
disorders described herein.
[0116] Slow or extended-release delivery systems, including any of
a number of biopolymers (biological-based systems), systems
employing liposomes, colloids, resins, and other polymeric delivery
systems or compartmentalized reservoirs, can be utilized with the
compositions described herein to provide a continuous or long term
source of therapeutic compound. Such slow release systems are
applicable to formulations for delivery via topical, intraocular,
oral, and parenteral routes.
[0117] An effective quantity of an elmiric acid or J acid is
employed in treatment. The dosage of compounds used in accordance
with the invention varies depending on the compound and the
condition being treated. For example, the age, weight, and clinical
condition of the recipient patient. Other factors include: the
route of administration, the patient, the patient's medical
history, the severity of the disease process, and the potency of
the particular compound. The dose should be sufficient to
ameliorate symptoms or signs of the disease treated without
producing unacceptable toxicity to the patient. In general, an
effective amount of the compound is that which provides either
subjective relief of symptoms or an objectively identifiable
improvement as noted by the clinician or other qualified observer.
Exemplary dosages of lipid-amino acid conjugates are 0.1 to 50
mg/kg, e.g., 0.1 to 20 mg/kg, 0.5 to 50 mg/kg, 0.1 to 2.0 mg/kg,
2.0 to 10 mg/kg, or 10 to 50 mg/kg body-weight of the patient.
[0118] Elmiric acids and J acids can also be given orally in
combination with natural or synthetic compounds that bind to or
modify the activity of the vitamin D receptor or in combination
with compounds that bind to or modify the activity of the retinoid
X receptor to provide for a synergistic effect in the treatment or
prevention of the disorders. Examples of such compounds that
provide for synergistic effect when given in combination with the
drugs encompassed by the current invention include vitamin D
analogs, various retinoic acid derivatives, and other activators
for retinoid X receptors or retinoic acid receptors including, but
not limited to, compounds such as LG100268, tazarotene, TTNPB, AGN
190121, adapalene, or LGD1069 (TARGRETIN.TM.).
EXAMPLES
[0119] The invention will be further described in the following
examples, which do not limit the scope of the invention described
in the claims.
Example 1
Synthesis of Arachidonoyl-D-Alanine
[0120] N-fatty acid-D-alanine conjugate was prepared from chirally
pure D-amino acid methyl ester (Aldrich Chemicals). Arachidonoyl
chloride (Nucheck) in methylene chloride was reacted with alanine
methyl ester in methylene chloride containing 5% triethylamine for
4 hours at room temperature. The mixture was partitioned between
ethyl acetate and dilute HCl, washed, dried and evaporated to an
oily residue. This residue was dissolved in tetrahydrofuran and
saponified by stirring under nitrogen with 1 N LiOH for 5 hours at
room temperature. The product was extracted as above and subjected
to thin layer chromatography. The principal product was identified
as N-arachidonoyl-D-alanine by mass spectrometric analysis and
exhibited an MH.sup.+ of 376.1. Circular dichroism measurements
showed mirror image spectra between 220 and 240 nm when compared to
the L isomer. The [.alpha.] values were -16.6.times.10.sup.5 for
the D isomer and +16.5.times.10.sup.5 for the L isomer.
Example 2
Synthesis of Other Elmiric Acids
[0121] The synthesis procedure of Example 1 was used to prepare the
arachidonyl and palmityl conjugates with 1-amino-cyclohexane
carboxylic acid, 1-amino-cyclopentane carboxylic acid, and
2-amino-isobutyric acid. The synthesized compounds were
N-palmitoyl-1-amino cyclohexane-COOH, N-palmitoyl-1
amino-cyclopentane-COOH, N-palmitoyl-2-amino-isobutyric acid,
N-arachidonoyl-1-amino-cyclohexane-COOH, and
N-arachidonoyl-1-amino-cyclopentane-COOH, and
N-arachidonoyl-2-amino-isobutyric acid.
Example 3
Synthesis of Other Elmiric Acids
[0122] A solution of 10 mg arachidonic acid (5Z, 8Z, 11Z,
14Z-eicosatetraenoic-5,6,8, 9, 11, 12, 14, 15 acid) is added to a
solution of N-hydroxysuccinimide (NHS) (4 mg) in 5 ml of ethyl
acetate, followed by the addition of 9 mg of
dicyclohexylcarbodiimide (CDI) to the solution. The mixture is
allowed to react for 24 hours at room temperature, followed by the
addition of 10 mg of amino acid in a mixture of
dioxane-KOH--NaHCO.sub.3 (2 ml). The resulting mixture is reacted
for an additional 48 hours at 4.degree. C. The mixture is then
acidified with HCl, extracted with ethyl acetate, and the
N-arachidonoyl-amino acid product is isolated by thin layer
chromatography (acetonitrile, 96; water, 4). The identity is
confirmed by NMR and mass spectral analysis.
Example 4
Synthesis of J Acids
[0123] A solution of 10 mg 15-deoxy-.DELTA..sup.12,14-prostaglandin
J.sub.2 is added to a solution of N-hydroxysuccinimide (NHS) (4 mg)
in 5 ml of ethyl acetate, followed by the addition of 9 mg of
dicyclohexylcarbodiimide (CDI) to the solution. The mixture is
allowed to react for 24 hours at room temperature, followed by the
addition of 10 mg of amino acid in a mixture of
dioxane-KOH--NaHCO.sub.3 (2 ml). The resulting mixture is reacted
for an additional 48 hours at 4.degree. C. The mixture is then
acidified with HCl, extracted with ethyl acetate, and the
N-15-deoxy-.DELTA..sup.12,14-prostaglandin J.sub.2-amino acid
product is isolated by thin layer chromatography (acetonitrile, 96:
water, 4). The identity is confirmed by NMR and mass spectral
analysis.
Example 5
Testing of Lipid-Amino Acid Conjugates
[0124] N-arachidonoyl-D-alanine is subjected to the Oil Red O
assay, discussed in more detail supra. In the assay, 3T3 L1
fibroblasts are cultured in DMEM supplemented with 10% calf serum.
Two days after confluence, cells are treated with 0.1% DMSO
(vehicle), 20-100 .mu.M N-arachidonoyl-D-alanine in vehicle, or 1
.mu.M GW347845 (Cobb et al., J. Med. Chem., 41:5055-5069, 1998) in
vehicle. Each of the three treatments is administered to the cells
with 10 .mu.g/ml of insulin. After seven days of treatment with
GW347845 and 10-14 days of treatment with N-arachidonoyl-D-alanine,
cells are fixed and stained with Oil Red O. Red staining indicates
lipid droplets in the cytoplasm.
[0125] RT-PCR analysis of expressed genes is performed as a
secondary test of adipocyte differentiation. Messenger RNA from
fibroblasts is harvested and RT-PCR is performed to amplify
adipocyte specific transcripts, e.g., PPAR.gamma.2 and aP2, or the
transcript of a ubiquitous housekeeping gene, e.g., GAPDH. PCR
products are analyzed on 1% agarose gel and stained with ethidium
bromide. PPAR.gamma.2 and aP2 are induced significantly after
treatment with 1 .mu.M GW347845 or after treatment with 20-100
.mu.M N-arachidonoyl-D-alanine relative to vehicle-treated cells.
Expression of the housekeeping gene GAPDH is assayed to ensure
equal expression in all samples.
Example 5
In Vivo Testing of Lipid-Amino Acid Conjugates
Paw Edema
[0126] Suppression of chemically induced paw edema in mice is a
long-standing assay for assessment of an agent's potential
anti-inflammatory activity. A lipid-amino acid conjugate, e.g., an
elmiric acid or a J acid, is tested in this model for inhibitory
effects on chemically induced edema.
[0127] Platelet activating factor (PAF) (1 .mu.g) or arachidonic
acid (1 mg) dissolved in 50 .mu.l of 5% ethanol in saline is
injected subcutaneously in the right hind paw of an anesthetized
mouse. Paw volume is measured by water displacement before
treatment and 15 minutes after PAF injection or 30 minutes after
arachidonate injection. Lipid-amino acid conjugates or control
compounds are given by gavage in safflower oil 90 minutes before
edema induction.
[0128] Animals are administered lipid-amino acid conjugates at
doses of 0.1, 0.5, 1.0, 5.0, 25, and 50 mg/kg or vehicle (0.05 ml
safflower oil) by gavage essentially as described (Burstein et al.,
J. Med. Chem., 35:3135-3141, 1992). Ten male CD-1 mice are used in
each group. Controls are vehicle, indomethacin at 2.0 mg/kg, and
ajulemic acid at 1.0 mg/kg. ED-50 values are obtained and compared
with control values. Paw volume changes are compared using a paired
t-test. Lipid-amino acid conjugates that reduce paw volume changes
by 50% are candidate anti-inflammatory agents.
Subcutaneous Air Pouch
[0129] The subcutaneous air pouch simulates a synovial lined joint
space by providing a blind connective tissue cavity without a
mesothelial basement membrane; the pouch lining has the two cell
types (fibroblasts and macrophage-like cells) common to synovia.
The pouch provides a way to induce and monitor the effect of a
lipid-amino acid conjugate, e.g., an elmiric acid or a J acid, on
an inflammatory response. The response to IL-1.beta. and TNF.alpha.
is typical of an acute inflammatory reaction, with
polymorphonuclear leukocyte infiltration of the pouch wall and
cavity increasing in a dose-dependent manner.
[0130] Pouches are established on the backs of female Swiss (CD-1)
mice by subcutaneous injection of 5 ml of air on three consecutive
days. After 6 days, animals (10 per group) are treated with the
appropriate agent, a lipid-amino acid conjugate or control, for 3
days (see below). Inflammation is induced on day 3 of treatment by
injection into the pouch cavity of 10 ng rhuIL-1.beta. plus 0.25 ng
rHuTNF.alpha. in 3 ml of 1% carboxymethylcellulose. Inflammation is
quantified 6 hours later by determination of pouch exudate volume
and leukocyte count.
[0131] Animals are administered analogs at doses of 0.1, 0.5, 1.0,
5.0, 25, and 50 mg/kg or vehicle (0.05 ml safflower oil) by gavage
as described (Zurier et al., Arthritis Rheum., 41: 163-170, 1998).
Controls are vehicle, indomethacin at 2.0 mg/kg, and ajulemic acid
at 1.0 mg/kg. ED-50 values are obtained and compared with control
values by ANOVA. Lipid-amino acid conjugates that reduce pouch
exudate volume or leukocyte count by 50% are candidate
anti-inflammatory agents.
Adjuvant Induced Arthritis Model of Chronic Inflammation and Tissue
Injury
[0132] The polyarthritis model of adjuvant disease in the rat has
been used extensively for evaluating anti-inflammatory and
immunosuppressive drugs. This model can be used to test the effect
of a lipid-amino acid conjugate, e.g., an elmiric acid or J acid,
on the severity of the inflammatory response.
[0133] Chronic polyarthritis is induced in male Lewis rats (initial
weight 125 gm) by intradermal injection of Freund's complete
adjuvant (2 mg Mycobacterium butyricum in 0.1 ml mineral oil) at
the tail base (N=8). Animals are anesthetized with sodium
pentobarbital during the procedure. Arthritis in all 4 paws is
assessed visually, and each paw is scored clinically for degree of
inflammation using a 0-4 scale (0=normal; 132 redness; 2=redness,
pain, slight swelling; 3=redness, severe pain, severe swelling; 432
ankylosis). An examiner who has no knowledge of the treatment
groups into which rats have been placed evaluates paws. Rats are
handled gently, and those with severe arthritis and extreme pain
are sacrificed. Weight change and activity are also recorded over
the course of the experiment.
[0134] Animals are either untreated, treated with safflower oil, or
treated with the lipid amino acid conjugates or controls in a
volume of 90-120 .mu.l (adjusted for animal weight) each day,
beginning on day 3 after adjuvant injection. Compounds are
administered with a 5 cm gavage needle. Joints are evaluated every
other day. Animals are sacrificed on day 35, and hind limbs are
then removed for histomorphologic examination. A dose range of 0.1,
0.5, 1.0, 5.0, 25, and 50 mg/kg of lipid-amino acid conjugate
administered thrice weekly is utilized. AJA (1.0 mg/kg) and
indomethacin (2.0 mg/kg) serve as controls.
[0135] Hind limbs of animals are fixed in 10% buffered formalin and
then decalcified in 10% formic acid. Several sections of each
tibiotarsal joint are stained with hematoxylin and eosin.
Individual sections are studied without knowledge of the treatment
groups into which animals are placed. Lipid-amino acid conjugates
that reduce inflammation score by 50% are candidate
anti-inflammatory agents.
Other Embodiments
[0136] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
* * * * *